



8 January 2018

**Motif Bio plc**  
**("Motif Bio" or the "Company")**

**Exercise of Warrants**

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from a warrant holder to exercise warrants representing 471,602 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 20.0p per warrant for total consideration of £94,320.40.

Application has been made for the 471,602 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on January 11, 2018. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 263,990,730 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

For further information, please contact:

**Motif Bio plc**

Graham Lumsden (Chief Executive Officer)  
Robert Dickey IV (Chief Financial Officer)

info@motifbio.com

**Peel Hunt LLP (NOMAD & BROKER)**

Dr Christopher Golden  
Oliver Jackson

+ 44 (0)20 7418 8900

**Northland Capital Partners Limited (BROKER)**

Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)

+44 (0)203 861 6625

**Walbrook PR Ltd. (FINANCIAL PR & IR)**

Paul McManus/Helen Cresswell/Lianne Cawthorne

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com

**MC Services AG (EUROPEAN IR)**

Raimund Gabriel

+49 (0)89 210 2280

raimund.gabriel@mc-services.eu

**The Trout Group (US IR)**

Meggie Purcell

+ 1 (646) 378-2936

mpurcell@troutgroup.com